ACAD — ACADIA Pharmaceuticals Inc. Stock Price, Chart & AI Report

Positive Dec 4, 2025 • 00:12 UTC The Motley Fool • Jonathan Ponciano

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.

ACAD KRYS NBIX biotechnology pharmaceuticals central nervous system investment stock performance

Sentiment note

Company demonstrated double-digit revenue growth, expanded sales for key drugs NUPLAZID and DAYBUE, more than doubled net income in Q3, raised full-year guidance, and attracted significant new investment from a biotech-focused fund

Positive Sep 11, 2025 • 03:30 UTC GlobeNewswire Inc. • Linda Lam

Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards Winners

Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.

SNY BHC ACAD PFE pharmaceutical marketing healthcare innovation awards marketing campaigns

Sentiment note

Recognized for innovative Influencer-Driven Campaign and Online Video/Film

Positive Apr 22, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight

The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.

ACAD AMRX MGTX LLY Parkinson's disease market growth emerging therapies treatment options

Sentiment note

The article mentions that Acadia Pharmaceuticals' drug pimavanserin (NUPLAZID) was the first FDA-approved treatment for Parkinson's disease psychosis, giving the company a first-mover advantage in this space.

Neutral Feb 11, 2025 • 08:48 UTC GlobeNewswire Inc. • Transparency Market Research

Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research

The global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.

BIIB MRK NVS TEVA neuroregeneration therapy regenerative medicine neurodegenerative disorders stem cell therapy

Sentiment note

Acadia Pharmaceuticals Inc. is mentioned as one of the leading companies in the neuroregeneration therapy market, but no specific details about their involvement or developments are provided.

Unknown Jun 27, 2024 • 12:41 UTC Benzinga • Avi Kapoor

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock. Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to ...Full story available on Benzinga.com

ACAD HOLX VRTX GRAB News Initiation Markets Analyst Ratings

Unknown Jun 24, 2024 • 10:49 UTC Zacks Investment Research • Zacks Equity Research

Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

ALNY ACAD

Unknown Jun 7, 2024 • 15:30 UTC Zacks Investment Research • Zacks Equity Research

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ACAD MRNA

Unknown May 9, 2024 • 09:59 UTC Zacks Investment Research • Zacks Equity Research

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

LGND ANIP ACAD ANVS

Unknown May 8, 2024 • 21:15 UTC Zacks Investment Research • Zacks Equity Research

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 150% and 0.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ACAD BFRI

Unknown May 7, 2024 • 21:40 UTC Zacks Investment Research • Zacks Equity Research

Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of 6.19% and 4.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

LGND ACAD

Unknown May 6, 2024 • 14:40 UTC Zacks Investment Research • Kinjel Shah

Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?

Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.

TEVA PRGO ACAD IOVA

Unknown May 2, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INSM ACAD